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We here disclose the total syntheses of the natural polyphenol JBIR-94 and two nonnatural 
analogs, whose structures are of interest for their bioactivity potential as radical scavengers. 
Although we initially attempted this by dually acylating both of putrecine’s amine nitrogens in a 
single pot, our endeavors with this method (which has been successfully reported by other 
groups) proved ineffectual. We accordingly opted for the lengthier approach of acylating each 
amine individually, which gratuitously prevailed and also aligns with separate literature precedent. 
Moreover, we here share our analysis of these target compounds’ cytotoxicities and IC50 values 













In the human body, the unavoidable exposure of living tissues to excess free radicals, such as 
reactive oxygen species, can result in oxidative modification of biomolecules.1 These events 
contribute to various disorders that include age-related degenerative conditions, mutagenesis, 
neural dysfunction, cancer, heart disease, and compromised immune health.2-5 The human body 
possesses enzymatic and nonenzymatic antioxidative machinery to scavenge and eliminate free 
radicals, which include the dynamic 1-5% of radical molecular oxygen that human cells naturally 
produce.1,5 However, the efficacy of these defense mechanisms decreases with age.1 
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Fortuitously, diets rich in fresh fruits and vegetables correlate with lowered frequency of the 
aforementioned maladies, presumably because such foods contain high concentrations of 
antioxidative molecules: in particular, of polyphenolic compounds, which often possess 
antimutagenic, anti-inflammatory, antimicrobial, and free-radical-oxygen-scavenging properties.6-
15 It follows, then, that long-term healthy eating might partly offset the negative health effects in 
play as we age. Beyond its relevance to health, radical oxidation is also associated with food 
decomposition, as it “affects food safety, color, flavor, and texture” by contributing to the 
deterioration of lipids.6 Thus, antioxidants might also enhance and preserve food quality.6,16-17 
 With our research focus on synthesizing small, bioactive natural molecules with potential 
implications for disease prevention, we took note of two polyphenolic compounds, JBIR-94 and 
JBIR-125 (1 and 2, Figure 1), which were discovered in 2012 by Takagi and Shin-ya as secondary 
metabolites of the bacterium Streptomyces R56-07.18 According to their report, when molecules 
1 and 2 were tested in an α-diphenyl-β-picrylhydrazyl (DPPH) assay, they exhibited free-radical-
scavenging IC50 potencies of 11.4 μM and 35.1 μM, respectively.18 By comparison, α-tocopherol, 
a potent, radical-scavenging form of vitamin E,19-20 gave an IC50 value of 9.0 μM in the same 
assay.18 Thus, the more active natural product, JBIR-94 (1), manifested radical-scavenging 
potency comparable to that of Vitamin E, a well-known dietary antioxidant.20 
 
 





As often occurs in the field of natural products, both 1 and 2 were isolated in scant amounts from 
their natural source: 1.3 mg (1) and 2.3 mg (2), respectively, from 2 L of bacterial fermentation 
broth.18 Thus, large-scale access to either compound for more extensive study would be most 
efficiently achieved through total synthesis. As molecule 1 was the more potent of the two, we 
focused on its assembly, which we reasoned would be facile, given its symmetry. Because 
polyphenols are often reported to be potent radical scavengers,7-15 we hypothesized that the 
hydroxyl groups in 1 would be necessary for bioactivity but that the methoxy groups would not. 
Thus, analog 3 (Figure 1), which retains the hydroxyl moieties of 1 but lacks its methoxy groups, 
might theoretically exert similar antioxidative potency, while analog 4, which lacks both, would 
not. With the goal of providing efficient access to these molecules for later analysis, we sought to 
develop their first total syntheses.  
Despite finishing this work in mid-2016,21 time and resource constraints precluded us from 
an earlier disclosure. Moreover, as we initially raced toward its completion, elegant syntheses of 
1 and 2,22 as well as a separate synthesis of 4,23 were published by other groups in late 2015, 
thereby diminishing the impact of our research. Nevertheless, that we are aware, analog 3 has 
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never been previously reported. Thus, this paper presents the first disclosed synthesis of 3. 
Additionally, we share here the results of a cytotoxicity study of 1, 3, and 4, which should aid 
further efforts in developing bioactivity profiles for these molecules. 
 
Results and discussion 
 
At the outset, we envisioned a highly efficient one-pot, three-molecule assembly of the JBIR core, 
for which some related transformations were known.24 Thus, trans-ferulic acid (5) was treated with 
H2 gas and 5% Pd/C to quantitatively furnish 6 (Scheme 1).25 At this point, we divergently 
converted 6 into differentially protected analogs 7a-c26-28 (yields shown in Scheme 1). We then 
individually coupled molecules 6 and 7a-c with putrecine (8) in a 2:1 ratio in anticipation of forming 
hydrocarbon-tethered diamides 1 (from 6) or 9a-c (from 7a-c), respectively. Coupling parameters 
were screened under Conditions A-D (Scheme 1, bottom-left inset). Unfortunately, all of these 
attempts failed and instead gave only complex mixtures, unreacted starting materials, or 
unidentifiable byproducts. This contrasts with the work of Sorensen and Taj, who reported using 





Scheme 1. Attempted three-molecule/one-pot assemblies of the JBIR-94 core. 
 
 
Although this setback’s exact cause was uncertain, we suspected detrimental interaction with our 
protecting groups—for instance, an amine displaing the acetyl appendage in 7a—or undesired 
cross-reactivity between chlorine and silicon when silyl ether 7b is treated with oxalyl chloride 
(Condition D).  
Thus, as an alternative approach (Scheme 2), we treated molecules 7a-b (7c was not 
attempted) with N-hydroxysuccinimide (10) and DCC to quantitatively form intermediates 11a-b, 
whose succinimidyl-functionalization has been reported elsewhere for assembling diamides.29 
However, our efforts to obtain 11a-b in pure form were plagued with difficulties and proved 
unsuccessful. Nevertheless, we individually reacted our impure intermediates 11 with putrecine 
(8) in a 2:1 molar ratio in anticipation of forming products 1 or 9a-b. Unfortunately, these 
endeavors were unsuccessful. Alternatively, we converted carboxylic acids 6 and 7a-b into their 
methyl ester derivatives (not shown), which we then reacted with 8 under conditions reported by 
McCluskey et al.30 These attempts also failed, which effectively ended our campaign to synthesize 






Scheme 2. Alternative approach to the JBIR-94 core via intermediates 11a-b. 
 
At this point, we turned to the more conservative, stepwise approach shown in Scheme 3. With 
concerns about potential amine cross-reactivity with acetyl or silyl protecting groups—and  
knowing of benzyl ethers’ general robustness, putative ease of deprotection, and unreactivity 
toward amines31—we focused exclusively on substrate 7c from this juncture. To avoid prior 
obstacles with the diamine functionality of putrecine (8), we opted for commercially available, t-
Boc-protected analog 12. Subsequent treatment of its free amine with 7c, EDCI, Et3N, and 
catalytic DMAP, followed by overnight recrystallization from 1:1 CH2Cl2/hexanes, furnished 13 
cleanly, in 88% yield. Deprotection was facilitated by exposure to TFA in toluene (Scheme 3). 
Extensive trial and error revealed that this reaction had to be quenched by adding enough 2M 
aqueous NaOH to bring the precipitated suspension to pH > 10. After extensive extraction (20x) 
with CH2Cl2, drying over MgSO4, concentration, and overnight recrystallization from 90% 
EtOAc/hexanes, product 14 was obtained in pure form in 82% yield. Renewed subjection to EDCI 
coupling with 7c then gave intermediate 9c in 85% yield (recrystallized from CH2Cl2), and Pd-
catalyzed hydrogenation concomitantly removed both benzyl groups to furnish JBIR-94 (1) in 84% 




Scheme 3. Completed synthesis of JBIR-94 (1). 
 
 
We next turned to analogs 3 and 4. Thus, commercial reactant 15a was converted over two steps 
to 15c, the methoxy-free surrogate of 7c (Scheme 4). Next, EDCI coupling with 12 provided 16 
quantitatively, and TFA-mediated deprotection formed 17 in 78% yield. Renewed coupling with 
15c then gave 18 in 53% yield, and subsequent deprotection afforded 3 in 92% yield (26% overall 








Scheme 4. Completed synthesis of JBIR-94 analog 3. 
 
 
The synthesis of diamide 4 was carried out by coupling 3-phenylpropionic acid (19) with 12 to 
afford 20 quantitatively (Scheme 5). Deprotection, followed by subsequent coupling with 19, then 









The cytotoxicities of JBIR-94 and analogs 3-4 were evaluated through a colorometric assay 
against A549 (CCL-185) (human small lung cancer) cells using MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) dye. For this, 200 μL of cell suspension in growth medium with 
5000 cells was seeded to the wells of a 96-well culture plate and incubated for 24 hours. The 
medium was removed, and the compounds were added to the cells across a concentration 
gradient (0.01, 0.1, 1.0, 10, and 100 µM) in growth medium. Our assay also included a control 
with only medium and a control with 1% 100X Triton in medium. Cells were then incubated for 48 
hours, and 20 μL of MTT dye (5 mg/mL stock) was added to each well and incubated for another 
5 hours. The medium was removed, the cells were washed with PBS (pH = 7.4), and the reduced 
MTT dye was dissolved in 100 µL of DMSO, with absorption being measured at 570 nm and 650 
nm. This experiment was performed in triplicate of triplicate, with mean cytotoxicities presented 
in Figure 2. Our results indicated that compound 4 has relative cell viability at around 55% at 100 
μM, whereas JBIR-94 and analog 3 are relatively more toxic, with cell viabilities at around 60%, 
even at 10 µM concentration. Moreover, JBIR-94 and compounds 3-4 have IC50 values of 52.88 






















































In conclusion, we disclose here the total syntheses of the natural product JBIR-94 (1), as well as 
nonnatural analogs 3 and 4. Although syntheses of 1 and 4 have been reported previously in the 
literature,22-23 compound 3 has not. Additionally, we measured the cytotoxicities and IC50 values 
of 1, 3, and 4 against A549 (CCL-185) human small lung cancer cells using an MTT colormetric 
assay. Our results indicated that analog 4 has relative cell viability at around 55%, whereas 1 and 
3 are relatively more toxic, with cell viabilities at around 60%, even at 10 µM concentration. 
Separately, 1, 3, and 4 have IC50 values of 52.88 ± 11.69 µM, 78.92 ± 8.92 µM, and >100 µM, 
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Supplementary data associated with this article, which include complete experimental procedures 
and spectral characterization (1H and 13C NMR), are available in the online version at.  
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